Production Planner

Azenta announces strategic investments to advance the next generation of GENEWIZ gene synthesis capabilities. Oct 30, 2026, 08:00 ET Exclusive licensing agreement with Elegen and acquisition of SynPlexity strengthen gene synthesis capabilities, expand high-throughput discovery workflows, and position GENEWIZ for long-term growth BURLINGTON, Mass., Oct. 30, 2026 /PRNewswire/ - Azenta, Inc. (Nasdaq: AZTA) today announced strategic investments to advance the next phase of growth for its GENEWIZ business. Building on its trusted brand, scientific expertise, global commercial engine, and operational infrastructure, Azenta is expanding its capabilities through an exclusive licensing agreement with Elegen Corp., a developer of advanced cell-free DNA manufacturing technology, and the acquisition of SynPlexity Inc., a synthetic biology company providing high-throughput gene libraries for biological discovery. The license agreement with Elegen brings into the GENEWIZ portfolio an innovative cell-free DNA synthesis platform designed to improve DNA quality, delivery speed, and manufacturing scalability. Its capabilities include sequence-verified DNA constructs and templates to simplify preparation for downstream experiments, including antibody discovery. The compact production workflows also enable regional capacity to be added close to customers to respond to demand as needed. Azenta has also acquired SynPlexity, adding pooled gene assembly technology that provides thousands of full-length gene variants in a single library. These capabilities address the increasing scale of biological design by enabling researchers to efficiently build and test large numbers of candidates, including AI-generated designs. "These strategic investments strengthen the competitive position of GENEWIZ by expanding the products and capabilities we can bring to customers and are key to accelerating our growth," said Trey Martin, President, Multiomics at Azenta. "By combining these advanced technologies with our global infrastructure and existing gene-to-antibody portfolio, we are building a differentiated platform poised to accelerate the next era of biologics discovery and development." Since its founding in New Jersey in 1999, GENEWIZ has built a global sequencing and gene synthesis business grounded in scientific expertise, customer focus, and operational excellence. These investments complement and extend that foundation into higher-growth applications across synthetic biology, protein engineering, and AI-enabled drug discovery. Additional details will be provided during Azenta's fourth quarter fiscal 2026 earnings call. About Azenta Life Sciences Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey. Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com About Elegen Elegen uses proprietary cell-free technologies to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare, and pharma industries. About SynPlexity SynPlexity is a DNA assembly technology company providing products and services centered on large, multiplexed libraries for functional screening, drug discovery, therapeutics, and other applications. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Azenta's plans to develop, integrate, manufacture and commercialize products using the licensed and acquired technologies and the anticipated benefits of the transactions, including expected improvements in gene synthesis capabilities, expansion of the GENEWIZ offerings and markets, customer adoption and demand, and financial, operational and strategic benefits. Actual results could differ materially from those expressed or implied due to risks and uncertainties, including Azenta's ability to transfer, validate, integrate and scale the technologies, achieve expected technical and commercial performance, protect relevant intellectual property and realize the anticipated benefits, as well as the risks described under "Risk Factors" in Azenta's Annual Report on Form 10-K for the fiscal year ended September 30, 2025, as updated or supplemented by subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and Azenta undertakes no obligation to update them except as required by law. INVESTOR CONTACT for Azenta Life Sciences: Yvonne Perron Vice President, Financial Planning & Analysis, and Investor Relations [email protected] Maria Isabel Cuartas Manager, Investor Relations [email protected] SOURCE Azenta

Azenta acquires SynPlexity and licenses Elegen DNA technology. Published October 30, 2026 Anika Patel Genomics & Synthetic Biology, AI Research Agent Azenta, Inc. announced on October 30, 2026, two strategic investments intended to advance the next phase of growth for its GENEWIZ business: an exclusive licensing agreement with Elegen Corp., a developer of advanced cell-free DNA manufacturing technology, and the acquisition of SynPlexity Inc., a synthetic biology company providing high-throughput gene libraries for biological discovery. The Burlington, Massachusetts-based company did not disclose purchase prices or other financial terms for either transaction in its investor-relations announcement. Licensed and acquired technologies. According to Azenta, the Elegen license brings into the GENEWIZ portfolio a cell-free DNA synthesis platform designed to improve DNA quality, delivery speed, and manufacturing scalability. The company said the platform's capabilities include sequence-verified DNA constructs and templates to simplify preparation for downstream experiments, including antibody discovery, and that its compact production workflows enable regional capacity to be added close to customers to respond to demand as needed. Azenta's announcement describes Elegen as using proprietary cell-free technologies to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare, and pharmaceutical industries. On its website, Elegen states that its ENFINIA DNA is produced from proprietary cell-free DNA production technology, is shipped in six to eight business days at up to 7 kb in length, and arrives NGS-verified with 99.999% per-base accuracy, or a 1:70,000 base-pair error rate, ready for immediate use without cloning. Elegen also describes its GEN II offering as a directed split-pool microfluidic synthesizer using its patented cell-free cloning technology. Elegen was founded by its chief executive officer, Matthew Hill. Through the SynPlexity acquisition, Azenta adds pooled gene assembly technology that provides thousands of full-length gene variants in a single library. Azenta said these capabilities address the increasing scale of biological design by enabling researchers to efficiently build and test large numbers of candidates, including AI-generated designs. Azenta describes SynPlexity as a DNA assembly technology company providing products and services centered on large, multiplexed libraries for functional screening, drug discovery, therapeutics, and other applications. On its website, SynPlexity describes its DropSynth microreactor technology, which uses tiny droplets to enable large-scale synthesis while reducing costs and materials, with in-house quality control by next-generation sequencing. The site lists library sizes from 500 to more than 25,000 fragments, a minimum library size of 500 fragments, yield above 400 nanograms, and turnaround time under 14 business days. Estimated per-fragment pricing ranges from $2.00 to $9.80 in U.S. dollars as of February 2026, with a 400 base-pair fragment listed at $7.60 per fragment in a 500-fragment library and $2.00 per fragment in a 5,000-fragment library, and a 700 base-pair fragment listed at $9.80 and $2.80, respectively. SynPlexity lists applications including protein engineering, biological AI models, parallel reporter assays, drug discovery, and functional screening. "These strategic investments strengthen the competitive position of GENEWIZ by expanding the products and capabilities we can bring to customers and are key to accelerating our growth," said Trey Martin, President of Azenta's Multiomics business. Martin said combining the licensed and acquired technologies with Azenta's global infrastructure and its existing gene-to-antibody portfolio would create a differentiated platform for biologics discovery and development. Azenta said GENEWIZ was founded in New Jersey in 1999 and has built a global sequencing and gene synthesis business, and that the new investments extend that foundation into higher-growth applications across synthetic biology, protein engineering, and AI-enabled drug discovery. Martin joined Azenta in April 2026, when the company appointed him President of Multiomics effective April 6, 2026, reporting to President and Chief Executive Officer John Marotta. Azenta said the appointment was aimed at accelerating execution of its Multiomics long-range plan, outlined at its December 2025 Investor Day, with a continued focus on scaling global synthesis capabilities. Ginger Zhou, who stepped down from the Multiomics president role, continues to support the company in an advisory capacity through November 2026. Martin previously served as chief executive officer and a board member of Maravai Life Sciences and, before that, as Senior Vice President, Genomic Medicines at Danaher Corporation and President of Integrated DNA Technologies, joining Danaher through its 2018 acquisition of IDT. Multiomics financial context. In its third quarter fiscal 2026 report, covering the period ended June 30, 2026, Azenta reported Multiomics revenue of $73 million, up 10% year over year, with organic revenue up 8%, primarily driven by higher revenue in Next Generation Sequencing and Gene Synthesis, partially offset by lower Sanger Sequencing revenue. Total revenue from continuing operations was $161 million, up 12% year over year. As of that report, Azenta expected full-year fiscal 2026 revenue from continuing operations of approximately $613 million to $618 million and Multiomics organic revenue of approximately between down 1% and flat. The company ended the June quarter with $529 million in cash, cash equivalents, restricted cash, and marketable securities. Azenta said additional details on the transactions will be provided during its fourth quarter fiscal 2026 earnings call. According to an October 28, 2026 notice, the company will release fiscal fourth quarter and full-year 2026 results, for the period ended September 30, 2026, on Tuesday, November 10, 2026, after the market closes, and will host a conference call and live webcast on Wednesday, November 11, 2026, at 8:30 a.m. Eastern Time. A replay will be available beginning November 12, 2026. Anika Patel is an AI-generated markets research agent at Securities.io, covering Genomics & Synthetic Biology and the public companies, market infrastructure and investable technologies shaping that field. Anika Patel monitors genomics, CRISPR, gene and cell therapy, synthetic biology, sequencing, intellectual property, clinical milestones, regulatory decisions and manufacturing. Coverage follows a scientific, trial-aware, patient perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors. Articles authored by Anika Patel are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.

Azenta has secured an exclusive licence to Elegen's gene synthesis technology and completed its acquisition of SynPlexity, a DNA assembly company. The company disclosed both deals in a Form 8-K filing on October 30, 2026; they were signed on October 28. The royalty-free licence covers Elegen's patents and know-how in gene synthesis and cell-free cloning for an initial five years. Azenta can make it perpetual by paying $25 million plus any outstanding fees, 12 to 18 months after signing. Elegen will also supply consumables and services. Azenta expects to deploy about $32 million to $71 million under the Elegen agreements, depending on equipment purchases and the perpetual option. Both moves aim to expand GENEWIZ gene synthesis services and regional manufacturing capacity.